Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan
Real-world data from thousands of Japanese patients shows how well newer lung cancer drugs actually work outside clinical trials.
This large nationwide Japanese database study (n=3,012) characterizes the real-world landscape of second-line treatment in HER2-mutant NSCLC following drug approvals, providing outcome benchmarks (ORR, DCR, time on treatment) beyond trial populations. The data serves as a critical reference for understanding real-world effectiveness of trastuzumab deruxtecan and other HER2-directed therapies in this molecularly defined NSCLC subgroup.
What the study was
- Study design
- Non-interventional retrospective cohort study
- Population
- Patients with HER2-mutant NSCLC receiving second-line treatment in Japan (C-CAT nationwide database)
- Sample size
- 3012
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Lung Cancer
Why it surfaced
Large real-world cohort (n=3,012) providing post-approval evidence for HER2-directed NSCLC therapy in a national database. Real-world outcomes in approved targeted therapy context; directly relevant to precision oncology watchlist. Japan C-CAT database provides unusually high-quality nationwide genomic + clinical linkage.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.